{
    "clinical_study": {
        "@rank": "28531", 
        "arm_group": [
            {
                "arm_group_label": "PF-05175157", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "A Phase 2a study to evaluate the effects of an investigational compound administered at 200\n      mg, twice daily (BID), for 6 weeks, with canagliflozin, in adult subjects with Type 2\n      Diabetes Mellitus (T2DM)."
        }, 
        "brief_title": "A 6-Week Study To Determine The Safety And Effect Of An Investigational Drug Given With Canagliflozin In Adults With Type 2 Diabetes Mellitus Taking Metformin", 
        "completion_date": {
            "#text": "April 2014", 
            "@type": "Actual"
        }, 
        "condition": "Type 2 Diabetes Mellitus", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with Type 2 Diabetes Mellitus  and treated with metformin at a dose greater\n             than or equal to 1000 mg for at least 3 months and are willing to switch to\n             canagliflozin from metformin for the duration of the study\n\n          -  Hemoglobin A1c of 7-10% at screening.\n\n          -  Body Mass Index of at least 25 kg/m2.\n\n        Exclusion Criteria:\n\n          -  Compliant with study drug administration during the run-in period and throughout the\n             trial.\n\n          -  Patients with fasting triglycerides greater than 500 mg/dL at screening.\n\n          -  History of certain diabetic complications or cardiac problems."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "8", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 30, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02053116", 
            "org_study_id": "B1731006"
        }, 
        "intervention": [
            {
                "arm_group_label": "PF-05175157", 
                "description": "Tablet, 200 mg, twice daily, 6 weeks", 
                "intervention_name": "PF-05175157", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Tablet, 0 mg, twice daily, 2 weeks", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 16, 2014", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B1731006&StudyName=A%206-Week%20Study%20To%20Determine%20The%20Safety%20And%20Effect%20Of%20An%20Investigational%20Drug%20Given%20With%20Canagliflozin%20In%20Adults%20With%20Type%202%20Diabetes"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "DeLand", 
                    "country": "United States", 
                    "state": "Florida", 
                    "zip": "32720"
                }, 
                "name": "Pfizer Investigational Site"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A 6-week Phase 2a Randomized, Double-Blind, Placebo-Controlled Study To Assess Safety, Tolerability And Pharmacodynamics Of Oral PF-05175157 Administered With Canagliflozin In Adult Subjects With Type 2 Diabetes Mellitus", 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Terminated", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Change from baseline in Weighted Mean Daily Glucose (WMDG) when compared to placebo", 
            "safety_issue": "No", 
            "time_frame": "Week 0, 4"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02053116"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change from baseline in Weighted Mean Daily Glucose (WMDG) when compared to placebo", 
                "safety_issue": "No", 
                "time_frame": "Weeks 0 and 4"
            }, 
            {
                "measure": "Change from baseline in fasting plasma glucose", 
                "safety_issue": "No", 
                "time_frame": "Weeks 0, 2, 4 and 6"
            }, 
            {
                "measure": "Change from baseline in Glycosylated Hemoglobin (HbA1c)", 
                "safety_issue": "No", 
                "time_frame": "Weeks 0, 4 and 6"
            }, 
            {
                "measure": "Change from baseline in fasting total cholesterol", 
                "safety_issue": "No", 
                "time_frame": "Weeks 0, 4 and 6"
            }, 
            {
                "measure": "Change from baseline in glucose AUC(0-5) during mixed meal tolerance test (MMTT)", 
                "safety_issue": "No", 
                "time_frame": "Weeks 0, 4 and 6"
            }, 
            {
                "measure": "Change from baseline in insulin AUC(0-5) during mixed meal tolerance test (MMTT)", 
                "safety_issue": "No", 
                "time_frame": "Weeks 0, 4 and 6"
            }, 
            {
                "measure": "Change from baseline in C-peptide AUC(0-5) during mixed meal tolerance test (MMTT)", 
                "safety_issue": "No", 
                "time_frame": "Weeks 0, 4 and 6"
            }, 
            {
                "measure": "Change from baseline in ratio of AUC(0-5) insulin to AUC(0-5) glucose during the MMTT", 
                "safety_issue": "No", 
                "time_frame": "Weeks 0, 4 and 6"
            }, 
            {
                "measure": "Change from baseline in ratio of AUC (0-5) C-peptide to AUC(0-5) glucose during the MMTT", 
                "safety_issue": "No", 
                "time_frame": "Weeks 0, 4 and 6"
            }, 
            {
                "measure": "Change from baseline in homeostatic model assessment for insulin resistance (HOMA IR)", 
                "safety_issue": "No", 
                "time_frame": "Weeks 0, 4 and 6"
            }, 
            {
                "measure": "Change from baseline in homeostatic model assessment for \u03b2-cell function (HOMA B)", 
                "safety_issue": "No", 
                "time_frame": "Weeks 0, 4 and 6"
            }, 
            {
                "measure": "Change from baseline in low density lipoprotein cholesterol (LDL-C)", 
                "safety_issue": "No", 
                "time_frame": "Weeks 0, 4 and 6"
            }, 
            {
                "measure": "Plasma concentrations for PF-05175157", 
                "safety_issue": "No", 
                "time_frame": "Weeks 2, 4 and 6"
            }, 
            {
                "measure": "Percent change from baseline in body weight", 
                "safety_issue": "No", 
                "time_frame": "Weeks 0, 4 and 6"
            }, 
            {
                "measure": "Change from baseline in high density lipoprotein cholesterol (HDL-C)", 
                "safety_issue": "No", 
                "time_frame": "Weeks 0, 4 and 6"
            }, 
            {
                "measure": "Change from baseline in triglycerides", 
                "safety_issue": "No", 
                "time_frame": "Weeks 0, 4 and 6"
            }, 
            {
                "measure": "Change from baseline in non-HDL cholesterol", 
                "safety_issue": "No", 
                "time_frame": "Weeks 0, 4 and 6"
            }, 
            {
                "measure": "Change from baseline in very low density lipoprotein (VLDL)", 
                "safety_issue": "No", 
                "time_frame": "Weeks 0, 4 and 6"
            }
        ], 
        "source": "Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "May 2014", 
        "why_stopped": "On 25April2014, study was terminated before any dosing due to an AE of safety concern that\n    occurred in protocol B1731003 with the same drug."
    }
}